Cyclohexane Derivatives Modulate PGI2 Receptor for Oral PAH Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pulmonary arterial hypertension (PAH) rely on intravenous prostacyclin analogs with short half-lives, requiring continuous infusion and posing risks of rebound pulmonary hypertension and catheter-related complications, while stable, orally-active prostacyclin analogs are needed for improved management and broader disease treatment.
Innovation Solution
Development of cyclohexane derivatives and their pharmaceutical compositions that modulate the activity of the PGI2 receptor, offering a therapeutically effective treatment for PAH and various associated conditions, including idiopathic and familial PAH, through administration of these compounds or compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intravenous prostacyclin analogs are used to treat PAH, then the therapeutic effect is achieved, but the half-life is short requiring continuous infusion
Solution Approach 1:
The patent modifies the chemical structure of prostacyclin analogs by changing molecular parameters (introducing cyclohexane derivatives with specific substituents at positions R1, R2, R3) to achieve both therapeutic efficacy and extended half-life. The specific chemical modifications allow the compound to maintain biological activity while improving pharmacokinetic properties.
Solution Approach 2:
The invention creates composite molecular structures combining cyclohexane core structures with various substituent groups (aryl, heteroaryl, alkyl groups) to achieve a balance between therapeutic activity and prolonged duration of action. This composite approach allows optimization of both pharmacological and pharmacokinetic properties.
2Reliability
If continuous infusion is used to maintain therapeutic effect, then the disease is controlled, but the risk of rebound pulmonary hypertension and catheter-related complications increases
Solution Approach 1:
The patent enables periodic dosing instead of continuous infusion by designing compounds with extended half-lives that maintain therapeutic effect between doses. This periodic administration approach eliminates the need for continuous IV infusion, thereby reducing catheter-related complications and rebound pulmonary hypertension risks.
Solution Approach 2:
The invention replaces the need for continuous IV infusion (a complex, high-risk system) with orally administered compounds that provide sustained therapeutic effect. The oral formulation acts as a simpler, safer alternative that eliminates catheter-related issues while maintaining disease control.
3Ease of operation
If orally-active prostacyclin analogs are developed, then ease of administration is improved, but stable analogs with adequate half-life are difficult to achieve
Solution Approach 1:
The patent systematically modifies molecular parameters of prostacyclin analogs by introducing cyclohexane derivatives with specific substituent patterns (R1, R2, R3 positions) to simultaneously achieve oral bioavailability and extended half-life. The chemical structure optimization enables both ease of administration and prolonged duration of action.
Solution Approach 2:
The invention develops composite molecular structures combining cyclohexane cores with various functional groups that provide both oral activity and stable pharmacokinetics. The composite nature of these molecules allows simultaneous optimization of absorption properties and half-life stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cyclohexane derivatives provide a stable, orally-active solution for treating PAH and related conditions, potentially reducing the risks associated with continuous infusion and improving management of PAH, while also being effective for other diseases mediated by the PGI2 receptor.
Implementation Method 1
the binding of PGI2 (or other such agonist) to the PGI2 receptor leads to coupling with the Gs protein and increases intracellular cAMP levels
Data Source
AI summary
Cyclohexane derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor.Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).